Related Experiment Video

Updated: May 17, 2026

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing
10:44

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing

Published on: May 5, 2023

Targeting the DNA-binding activity of the human ERG transcription factor using new heterocyclic dithiophene

Raja Nhili1, Paul Peixoto, Sabine Depauw

  • 1INSERM UMR837-JPARC, Team 4, Molecular and Cellular Targeting for Cancer Treatment, University of Lille North of France, IMPRT-IFR114, Institut pour la Recherche sur le Cancer de Lille, Place de Verdun, Lille F-59045, France.

Nucleic Acids Research
|October 25, 2012
PubMed

Insights

Researchers identified a novel compound, DB1255, that inhibits the binding of the ERG transcription factor to DNA. This discovery offers a new strategy for cancer treatment by directly modulating gene expression in leukemia and prostate cancer.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Drug Discovery

Background:

  • Directly targeting oncogenic transcription factors for cancer therapy is an emerging field.
  • The ERG (E-twenty-six) transcription factor is implicated in leukemia and prostate carcinoma due to overexpression or translocation.

Purpose of the Study:

  • To identify and characterize small molecules that inhibit the interaction between the ERG transcription factor and its DNA binding site.
  • To validate the efficacy of identified inhibitors in both in vitro and cellular models.

Main Methods:

  • High-throughput screening of synthetic inhibitors for ERG/DNA binding.
  • Electrophoretic mobility shift assays (EMSA) for validation.
  • Spectrometry, footprinting, and surface plasmon resonance (SPR) analyses for interaction characterization.
  • In cellulo luciferase assays to confirm gene expression modulation.

Main Results:

  • The compound DB1255 was identified as a potent inhibitor of ERG/DNA binding.
  • DB1255 exhibits sequence selectivity and binds to the DNA groove as a dimer.
  • Structure-activity relationship studies were performed on DB1255 derivatives.
  • DB1255 protected the ERG-binding site on the Osteopontin promoter from DNaseI digestion in cellular assays.

Conclusions:

  • DB1255 effectively modulates ERG/DNA complex formation both in vitro and in cellulo.
  • This heterocyclic diamidine specifically targets a key region of the ERG DNA recognition site.
  • These findings represent a significant advancement in developing targeted therapies for ERG-driven cancers.

More Related Videos

Genome-wide Mapping of Drug-DNA Interactions in Cells with COSMIC (Crosslinking of Small Molecules to Isolate Chromatin)10:05

Genome-wide Mapping of Drug-DNA Interactions in Cells with COSMIC (Crosslinking of Small Molecules to Isolate Chromatin)

Published on: January 20, 2016

Enhanced Yeast One-hybrid Screens To Identify Transcription Factor Binding To Human DNA Sequences11:25

Enhanced Yeast One-hybrid Screens To Identify Transcription Factor Binding To Human DNA Sequences

Published on: February 11, 2019

Related Concept Videos

Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Cooperative Binding of Transcription Regulators02:13

Cooperative Binding of Transcription Regulators

Transcriptional regulators bind to specific cis-regulatory sequences in the DNA to regulate gene transcription. These cis-regulatory sequences are very short, usually less than ten nucleotide pairs in length. The short length means that there is a high probability of the exact same sequence randomly occurring throughout the genome.  Since regulators can also bind to groups of similar sequences, this further increases the chances of random binding. Transcriptional regulators form dimers that...
Eukaryotic Transcription Activators02:42

Eukaryotic Transcription Activators

Transcription activators are proteins that promote the transcription of genes from DNA to RNA. In most cases, these proteins contain two separate domains ‒ a domain that binds to DNA and a domain for activating transcription; however, in some cases, a single domain is responsible for both binding and activation of transcription, as seen in the glucocorticoid receptor and MyoD.
The binding domains are capable of recognizing and interacting with regulatory sequences on the DNA. These domains are...